Last updated:
Author(s):
Hye In Kim, Christopher DeBoever, Klaudia Walter, Georgios Kalantzis, Chen Li, Sahar V. Mozaffari, Kousik Kundu, Benjamin M. Jacobs, Pedrum Mohammadi-Shemirani, Anthony M. Musolf, Jonathan M. Davitte, Melis A. Aksit, Joseph Gafton, Katrina A. Catalano, Adem Y. Dawed, Robert R. Graham, Bin Guo, Namrata Gupta, Teng Hiang Heng, Karen A. Hunt, Vivek Iyer, Claudia Langenberg, Frederik H. Lassen, Daniel G. MacArthur, Eamonn R. Maher, Cyrielle Maroteau, William G. Newman, Stephen O'Rahilly, Duncan S. Palmer, Iaroslav Popov, Moneeza K. Siddiqui, Michael A. Simpson, Marie Spreckley, John Wright, Guillermo del Angel, Slavé Petrovski, Emily R. Holzinger, Joseph C. Maranville, Laura Addis, Richard M. Turner, Karol Estrada, Simone Longerich, Joanna M. M. Howson, Yalda Jamshidi, Eric B. Fauman, Melissa R. Miller, Dorothée Diogo, Richard C. Trembath, Sarah Finer, Hilary C. Martin, David A. van Heel
Publish date:
27 March 2026
Journal:
Nature Genetics
PubMed ID:
41896352

Abstract

Genes & Health (G&H) is a biomedical study of adult British Pakistani and Bangladeshi research volunteers enriched for autozygosity. Here we performed whole-exome sequencing in 44,028 G&H participants, establishing a large publicly available South Asian exome resource linked to longitudinal electronic health records. We performed exome-wide association analyses for 645 electronic health record-derived traits under additive and recessive models, and meta-analyses of 33 cardiometabolic traits with UK Biobank, finding more than 100 novel gene-phenotype associations. We identified 2,991 genes with rare biallelic predicted loss-of-function (‘knockout’) genotypes, 546 of which had not been previously reported. We show that drugs targeting genes with knockouts in adults are associated with a 2.2-fold higher likelihood of progressing beyond phase 1 clinical trials. We further illustrate how phenotypic profiles associated with knockout genotypes can enhance efficacy and safety assessment of drug targets and aid in the interpretation of variants with ambiguous clinical significance in autosomal recessive disease genes.

Related projects

1. The primary scientific goal of the research is to apply human genetics to the identification of new drug targets, the validation of existing targets…

Institution:
Regeneron Genetics Center, LLC, United States of America

Some individuals that appear to be at high risk of developing disease based on their genes never develop or have a mild form of disease.

Institution:
Maze Therapeutics, Inc, United States of America

All projects